Dong-ki Lee
Company: OliX Pharmaceuticals
Job title: Founder & Chief Executive Officer
Seminars:
Reversing Liver Fibrosis: A Combination of Anti-NASH siRNA & Semaglutide 11:00 am
Identifying genomic variants from a large group of patients to derive robust targets Delving into the effects of weight loss to due to energy expenditure compared to incretin-based drugs Disentangling the forthcoming combination studies to increase the efficacy of reversing liver fibrosis and inducing reduction of liver fat contentRead more
day: Day 2 Seminar A Pre-Lunch Tracks